Composition containing group B meningococcal fHBP antigen as well as preparation method and application thereof

A meningococcal and composition technology, applied in the field of biomedicine, can solve problems such as insufficient immunogenicity, and achieve the effects of facilitating expression and purification, widening antigen spectrum, and improving immune effect

Pending Publication Date: 2020-03-06
苏州聚微生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the fHBP antigen provided by the prior art also has the problem of insufficient immunogenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing group B meningococcal fHBP antigen as well as preparation method and application thereof
  • Composition containing group B meningococcal fHBP antigen as well as preparation method and application thereof
  • Composition containing group B meningococcal fHBP antigen as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0029] According to one aspect of the present invention, the present invention also relates to a method for preparing a composition comprising group B meningococcal fHBP antigen as described above, comprising the following steps:

[0030] Obtaining recombinant plasmids, which respectively contain coding genes capable of expressing V1, V2 and V3;

[0031] Transforming the recombinant plasmids into host cells respectively, identifying, screening and identifying correct positive strains, and transforming the correctly identified positive strains into expression cells; culturing;

[0032] V1, V2 and V3 are isolated and enriched from the expressing cells and mixed with an optional adjuvant.

[0033] In some embodiments, the encoding genes capable of expressing V1, V2 and V3 are:

[0034] a) sequentially as shown in SEQ ID NO: 4-6; or

[0035] b). A sequence that encodes the same protein as the nucleotide sequence of a), but differs from the nucleotide sequence of a) due to codon ...

Embodiment

[0054] 1. Construction of recombinant plasmids

[0055] Three fHBP genes with P4 signal peptide were artificially synthesized by means of genetic engineering.

[0056] B01(V1)-fHBP nucleotide sequence (the italic bold part is the P4 signal peptide nucleotide sequence):

[0057]

[0058] The expressed protein sequence is as follows (the bold part in italics is the amino acid sequence of the P4 signal peptide, and the rest corresponds to SEQ ID NO: 1):

[0059]

[0060] A19(V2)-fHBP nucleotide sequence (the italic bold part is the P4 signal peptide nucleotide sequence):

[0061]

[0062] The expressed protein sequence is as follows (the bold italic part is the amino acid sequence of the P4 signal peptide, and the rest corresponds to SEQ ID NO:2):

[0063]

[0064] A05(V3)-fHBP nucleotide sequence (the italic bold part is the P4 signal peptide nucleotide sequence)

[0065]

[0066] The expressed protein sequence is as follows (the bold part in italics is the ami...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of biomedicine, in particular to a composition containing group B meningococcal fHBP antigen as well as a preparation method and an application thereof. The composition comprises recombinant proteins V1, V2 and V3 of variants 1, 2 and 3 of group B meningococcal fHBP; wherein the amino acid sequences of V1, V2 and V3 are sequentially shown as SEQ ID NO: 1-3, and V1, V2 and V3 have lipid modification. Compared with an existing vaccine, the composition has a wider antigen spectrum, can cover more types of variant strains and is good in immune effect.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a composition containing group B meningococcal fHBP antigen, a preparation method and application thereof. Background technique [0002] Neisseria meningitidis is a Gram-negative encapsulated bacterium that colonizes the upper respiratory tract of approximately 10% of the human population. Based on the structure of the capsular polysaccharide, meningococci can be divided into 13 serogroups. Among them, groups A, B, C, Y and W135 are the main pathogenic bacteria, which can cause more than 95% of cases. In my country and other countries such as Europe and the United States, more than 1 / 3 of meningitis caused by group B strains have become the main pathogenic bacteria. For groups A, C, W135 and Y, capsular polysaccharides can be used as vaccine antigens to prepare vaccines to prevent diseases. However, this method cannot be used for serogroup B. Because its capsular polysaccharide pol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/095A61K39/39A61K39/40A61P31/04C12N15/70C12N15/62
CPCA61K39/095A61K39/39A61K39/40A61P31/04C12N15/70C07K14/22A61K2039/55555A61K2039/55505C07K2319/02C07K2319/50
Inventor 胡浩陈瑞勤蒋浩然于旭博
Owner 苏州聚微生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap